New River Pharmaceuticals — Technical Presentation (June 2006)
46 slides from New River Pharmaceuticals's technical presentation, Jun 26, 2006

Slide 1: Lisdexamfetamine Dimesylate (NRP104/LDX) Clinical Abuse Liability Studies
Donald R. Jasinski, M.D. The Johns Hopkins University Baltimore, MD Lisdexamfetamine Dimesylate (NRP104 / LDX) Clinical Abuse Liability Studies

Slide 2: Forward-Looking Statements
This presentation may contain forward-looking Forward-Looking Statements statements that reflect management’s current views as to New River Pharmaceuticals Inc.’s clinical trials, regulatory approval process, product development, research programs and other future events and operations. These forwar

Slide 3: Single-Blind Single-Dose Escalation Study of NRP104 up to 150 mg
A Single-Blind, Placebo- and Active- Controlled, Single-Dose Escalation Study of NRP104 (up to 150 mg) to Evaluate Safety, Tolerability, and Abuse Liability in Healthy Adult Volunteers with Histories of Stimulant Abuse

Slide 4: Study A01 Design
1 Yes 40 30 50 70 100 2 Yes 40 50 70 100 130 3 Yes 40 70 100 130 150 Study A01 3 Cohorts of 4 subjects each each of 12 subjects received 4 single doses of NRP104 Minimum 2-day interval between dosing PK and PD measures before dosing and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 16 and 24 hours after dos

Slide 5: Study A01 Subject Eligibility
Study A01 All subjects had history of stimulant abuse No other clinically significant Axis I psychiatric disorders Could not be currently physically dependent on benzodiazepines (urine drug screen) opiates (naloxone challenge, 0.4 mg and 1 mg) ETOH (Breathalyzer test) No concomitant medications allo

Slide 6: Demographics and Baseline Characteristics
Age, years Mean ± SD Median (range) 43 ± 5.9 44 (29 - 52) Sex, n (%) Male 12 (100) Race, n (%) White Black Asian 1 (8.3) 10 (83.3) 1 (8.3) Height, cm Mean ± SD Median (range) 172.8 ± 6.7 174 (160 - 183) Weight, kg Mean ± SD Median (range) 74.6 ± 10.8 72 (58 - 94) REALM test score Mean ± SD Median (r

Slide 7: Study A01 Subject Disposition
Study A01 12 subjects were enrolled, randomized, and received at least 1 dose 11 subjects completed the study 1 subject was withdrawn due to “reactive hypertensive” after the second dose of d-a mphetamine not deemed a withdrawal caused by an adverse event Subject Disposition –

Slide 8: Study A01 Cohort 1 Dosing
Study A01 Four subjects completed NRP104 30, 50, 70, 100 mg Cohort –

Slide 9: Study A01 PK Data: Cohort 1 Concentration-Time Plots
Study A01 = 4 0.0 4.0 8.0 12.0 16.0 20.0 24.0 NRP104 mg NRP104 mg NRP104 mg NRP104 mg d -Amphetamine sulfate 40 mg Placebo PK Data: Cohort 1 Mean d-amphetamine Concentration‑Time Plots

Slide 10: Study A01 Cohort 2 Dosing
Study A01 Four subjects completed NRP104 50, 70, 100, 130 mg Cohort –

Slide 11: Study A01 PK Data: Cohort 2 Plots
Study A01 PK Data: Cohort 2 Mean d-amphetamine Concentration- Time Plots

Slide 12: Study A01 PK Data: Cohort 2 Plots
Study A01 PK Data: Cohort 2 Mean d-amphetamine Concentration- Time Plots

Slide 13: Study A01 Cohort 3 Dosing
Study A01 Three of four subjects completed NRP104 70, 100, 130, 150 mg Cohort –

Slide 14: Study A01 PK Data: Cohort 3 Plots
Study A01 = 3 or 4 0.0 4.0 8.0 12.0 16.0 20.0 24.0 NRP104 mg NRP104 mg NRP104 mg NRP104 mg d-Amphetamine sulfate 40 mg Placebo PK Data: Cohort 3 Mean d-amphetamine Concentration‑Time Plots

Slide 15: Study A01 PK Data: Cohort 3 Plots
Study A01 PK Data: Cohort 3 Mean d-amphetamine Concentration‑Time Plots

Slide 16: Study A01 Summary
Study A01 Overall, d- amphetamine produced the expected subjective, behavioral, and cardiovascular effects that were distinguished from placebo Comparable doses of NRP104 tended to be less euphoric overall and more dysphoric with a later peak effect PK and PD data consistent with pre-clinical studie

Slide 17: Double-Blind Crossover Study of Intravenous NRP104 25 mg and 50 mg
A Double- Blind Placebo- and Active- Controlled, Single-Dose Crossover Pharmacodynamic and Pharmacokinetic Study to Evaluate the Safety, Tolerability and Abuse Liability of Intravenously administered NRP104 25 mg and 50 mg in Healthy Adult Volunteers with Histories of Stimulant Abuse

Slide 18: Study Design
Phase II, randomized, single-center, double-blind dose run-up study Conducted at an in-patient residential unit subjects confined to clinic for a minimum of 14 days Included a screening phase and an NRP104 dose run-up phase Design –

Slide 19: Subject Population
≥ 18 and ≤ 55 years of age Meet DSM-IV criteria for the diagnosis of substance abuse Have a history of IV drug use Not physically dependent on benzodiazepines, opiates, or alcohol Minimal reading level of grade 6, determined by the Rapid Estimation of Adult Literacy in Medicine (REALM) at investigat

Slide 20: Primary Objectives
Investigate safety and abuse liability of a single intravenous (IV) dose of NRP104 in healthy adults with a history of stimulant abuse Compare safety profile with d -amphetamine and placebo Gather estimates of abuse liability Primary Objectives

Slide 21: Treatment
1 3 25 mg 10 mg Yes 2 9 50 mg 20 mg Yes Each subject received 1 single IV dose of NRP104, 1 single IV dose of d-amphetamine sulfate, and 1 placebo IV dose Minimum 2-day interval between dosing 3-way crossover drug administration Cohort Subject, NRP104 d -amphetamine Placebo Treatment

Slide 22: Assessments
Abuse liability assessments Drug Rating Questionnaire – Subject (DRQS) Drug Rating Questionnaire – Observer (DRQO) Treatment Enjoyment Assessment Questionnaire (TEAQ) Addiction Research Center Inventory (ARCI) – to assess the degree of amphetamine like effects with Amphetamine and Benzedrine Group S

Slide 23: Subject Disposition
12 Subjects were enrolled, randomized, and received at least 1 dose All 12 subjects completed the study There were no protocol deviations on inclusion/exclusion criteria and no subjects were withdrawn due to protocol violations Subject Disposition

Slide 24: Demographics and Baseline Characteristics
Age, years Mean ± SD Median (range) 45.9 ± 3.3 45.5 (42 - 52) Sex, n (%) Male 12 (100) Race, n (%) White Black 1 (8) 11 (92) Height, cm Mean ± SD Median (range) 176 ± 7.1 175.7 (159.5 - 185.4) Weight, kg Mean ± SD Median (range) 69.5 ± 10.3 68.8 (53.5 - 91.2) Characteristic = 12 Demographics and Bas

Slide 25: PK Data: Cohort 1 Semi-Logarithmic Plots
PK Data: Cohort 1 Mean d-amphetamine Concentration‑Time Plots in Semi‑Logarithmic Scales A = 25 mg NRP104 B = 10 mg Dextroamphetamine C = Placebo

Slide 26: DRQS Feel Drug Effect: Cohort 1
Do you feel a drug effect now? Mean response 0.00 5.00 10.00 15.00 20.00 Time, hr 0.00 5.00 10.00 15.00 20.00 Time, hr 0.00 5.00 10.00 15.00 20.00 Time, hr NRP104 mg Placebo d-amphetamine 10 mg DRQS – Feel Drug Effect: Cohort 1

Slide 27: DRQS Liking: Cohort 1
Do you like the drug effect you are feeling now? Mean Response 2.5 5.0 7.5 10.0 NRP104 mg 0.00 5.00 10.00 15.00 20.00 Time, hr Placebo 0.00 5.00 10.00 15.00 20.00 Time, hr d-amphetamine 10 mg 0.00 5.00 10.00 15.00 20.00 Time, hr DRQS – Liking: Cohort 1

Slide 28: Treatment Enjoyment Assessment Questionnaire: Cohort 1
1 1 d-amphetamine 10 mg 2 3 d-amphetamine 10 mg 3 4 d-amphetamine 10 mg Drug Chosen to Take Again Subject Drug Treatment Enjoyment Assessment Questionnaire: Cohort 1

Slide 29: PK Data: Cohort 2 NRP104 Concentration-Time Plots
D = 50 mg NRP104, E = 20 mg Dextroamphetamine, F = Placebo D = 50 mg NRP104 E = 20 mg Dextroamphetamine F = Placebo PK Data: Cohort 2 Mean NRP104 Concentration-Time Plots

Slide 30: PK Data: Cohort 2 d-amphetamine Semi-Logarithmic Plots
D = 50 mg NRP104 E = 20 mg Dextroamphetamine F = Placebo PK Data: Cohort 2 Mean d-amphetamine Concentration-Time Plots Semi‑Logarithmic Scales

Slide 31: Pharmacokinetic Parameters for NRP104
T1/2, h 0.72 ± 0.09 1.25 ± 1.13 AUC0-24, ng · hr/mL 281.9 ± 104.0 598.7 ± 232.9 Cmax, ng/mL 1150 ± 710 1570 ± 779 Tmax, hr 0.09 ± 0.01 0.18 ± 0.20 Mean ± SD Parameters NRP104 25 mg (n = 3) NRP104 50 mg (n = 9) Pharmacokinetic Parameters for NRP104

Slide 32: Pharmacokinetics Summary
T max of d- amphetamine after the administration of 25 or 50 mg NRP104 was substantially longer than after 10 or 20 mg d- amphetamine sulfate, respectively C max of d- amphetamine after administration of 25 or 50 mg NRP104 was substantially lower (3 to 4 fold) than the C max after administration of

Slide 33: DRQS Feel Drug Effect: Cohort 2
Do you feel a drug effect now? Mean response 0.00 5.00 10.00 15.00 20.00 Time, hr 0.00 5.00 10.00 15.00 20.00 Time, hr 0.00 5.00 10.00 15.00 20.00 Time, hr NRP104 mg Placebo d-amphetamine 20 mg DRQS – Feel Drug Effect: Cohort 2

Slide 34: DRQS Liking: Cohort 2
Do you like the drug effect you are feeling now? Mean Response NRP104 mg Placebo d-amphetamine 20 mg 0.00 5.00 10.00 15.00 20.00 Time, hr 0.00 5.00 10.00 15.00 20.00 Time, hr 0.00 5.00 10.00 15.00 20.00 Time, hr DRQS – Liking: Cohort 2

Slide 35: Summary DRQ Measures Cohort 2
Liking Disliking A = d -Amphetamine; P = Placebo. * P < 0.05 compared with placebo. Summary DRQ Measures Cohort 2 (n = 9)

Slide 36: Correlation Between d-Amphetamine Plasma Levels and Liking Measures
NC = Not calculable; P = Placebo. * P < 0.05. NC NC NC NRP104, mg d -Amphetamine Correlation Between Mean d- Amphetamine Plasma Levels and the Likin g Measures

Slide 37: Treatment Enjoyment Questionnaire: Cohort 2
1 2 None of the treatments 2 5 d-amphetamine 20 mg 3 6 d-amphetamine 20 mg 4 7 None of the treatments 5 8 NRP104 50 mg 6 9 d-amphetamine 20 mg 7 10 d-amphetamine 20 mg 8 11 d-amphetamine 20 mg 9 12 d-amphetamine 20 mg Drug Chosen to Take Again Subject Drug Treatment Enjoyment Questionnaire: Cohort

Slide 38: Conclusions
In this IV abuse liability study, NRP104 had less euphoric effects compared to equal doses of d- amphetamine sulfate NRP104 was significantly less reinforcing than d- amphetamine sulfate as evidenced by the majority of the subjects choosing not to take lisdexamfetamine dimesylate again, in the Treat

Slide 39: Six-Period Crossover Study of Likeability, Safety and Abuse Liability (NRP104.A03)
A Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study to Evaluate the Likeability, Safety, and Abuse Liability of NRP 104 in Healthy Adult Volunteers with Histories of Stimulant Abuse (NRP104.A03)

Slide 40: Design and Methods
30 male and 6 female stimulant abusers Six 6X6 balanced Latin squares for crossover design Primary variable is maximum score on VAS scale to item “ How much do you like the drug effects you are feeling now?” Design and Methods

Slide 41: Drug and Doses Given Orally
Placebo 40 mg d-amphetamine (Schedule II) 200 mg diethylpropion (Schedule IV) Pro-drug Subjective and behavioral effects comparable to d-amphetamine 40 mg Lisdexamfetamine 50 mg (base = d-amp 20 mg) 100 mg (base = d-amp 40 mg) 150 mg (base = d-amp 60 mg) Drug and doses given orally – – – – –

Slide 42: Primary Endpoint - Peak Liking Score
Dependent Variable: Do you like the drug effect you are feeling now? Based on observed means * - The mean difference is significant at the 0.05 level Drug (I) Drug (J) Mean Difference (I - J) Std. Error Significance 95% Conf. Interval (Lower Bound) d-amphetamine 40 mg Placebo 4.53* 1.148 < 0.001 1.9

Slide 43: Primary Endpoint: Peak Liking Score
Dependent Variable: Do you like the drug effect you are feeling now? Based on observed means * - The mean difference is significant at the 0.05 level Drug (I) Drug (J) Mean Difference (I - J) Std. Error Significance 95% Conf. Interval (Lower Bound) LDX 50 mg Placebo 1.97 1.148 0.148 -0.61 LDX 100 mg

Slide 44: Peak Liking Scores
d-amphetamine and diethylpropion 1.5 to 2 hours NRP104 3 to 4 hours Peak Liking Scores – –

Slide 45: Top Line Results
LDX attenuates onset and intensity of liking effects Liking effects of LDX 50 and 100 mg not significantly different than placebo Liking effects of LDX 150 mg greater thanplacebo but similar to d-amphetamine and diethylpropion; however, mean peak effect delayed Top Line Results

Slide 46: Top Line Results
Rate-limited hydrolysis of LDX in humans Pro-drug attenuates onset and intensity of amphetamine-like effects Attenuated Liking Scale scores Less reinforcing than equivalent d-amphetamine or diethylpropion Contribute to lesser abuse potential Top Line Results – –
Source: SEC EDGAR · 8-K filed Jun 26, 2006
More decks from New River Pharmaceuticals Inc
Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 20078 slides · Feb 6, 2007
Bear Stearns 19th Annual Investor Conference 200614 slides · Sep 12, 2006
Technical Presentation (June 2006)8 slides · Jun 20, 2006
Technical Presentation (June 2006)19 slides · Jun 19, 2006
Merrill Lynch Healthcare Conference 200610 slides · Feb 7, 2006
First Albany Capital Annual Growth Conference 200521 slides · Dec 7, 2005